Nervous System Diseases Paediatrics
Conditions
Interventions
Memantine 0.25mg
Memantine 0.15mg
Placebo
Sponsors
Self sponsor
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Primary epileptic patients of age range 8-18 years. Both sexes will be included. Focal or generalized controlled epilepsy with at least one month duration.
Exclusion criteria
Exclusion criteria: Intellectual disabilities with severe developmental disorders -History of prenatal or natal incidence causing developmental disorders. -Progressive and metabolic disorders leading to epileptic seizures. -Prior epilepsy surgery. -Known hypersensitivity to memantine. -Renal or liver impairment. -Epilepsy with psychological disorder AS, ADHD. -Antiepiletic that make memory impairment as topiramate and phenytoin.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Investigate effect different doses of memantine in improving working and visual memory in a sample of controlled childhood epilepsy. | — |
Secondary
| Measure | Time frame |
|---|---|
| Investigate effect different doses of memantine in improving verbal and performance IQ in a sample of controlled childhood epilepsy. | — |
Countries
Egypt
Contacts
Public ContactMaha Nada
Professor of Neurology Ain Shams University
Outcome results
None listed